Neisseria meningitidis is a common cause of bacterial meningitis, often leading to permanent sequelae or death. N. meningitidis is classified into serogroups based on the composition of the bacterial capsular polysaccharide...
Results of a Phase IIb/III placebo-controlled clinical trial of 4CMenB, from Novartis, in which 1631 adolescents received the vaccine, suggest...
Trumenba (bivalent rLP2086) is a vaccine licensed for the prevention of meningococcal meningitis disease caused by Neisseria meningitidis serogroup B (NmB) in individuals 10-25 years of age in the USA.
New results show that Lipoprotein 2086, a new vaccine for serogroup B Neisseria meningitidis, from Pfizer, is safe and immunogenic...
Novartis has announced the submission of a Biologic License Application (BLA) to the FDA for marketing approval for the use...
Pfizer announced positive topline results of two Phase III studies of Trumenba (meningococcal group B vaccine). One study included approximately...
Background: In February 2015, two unlinked culture-confirmed cases of Neisseria meningitidis serogroup B (MenB) disease occurred at a local college in Rhode Island ("college X") within 3 days.
The European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Trumenba (Meningococcal Group B Vaccine), from Pfizer,...
Purpose of review: Membranous nephropathy is an autoimmune disease caused by antibodies mostly directed to podocyte antigens.
Novartis has announced that the FDA has granted accelerated approval of Bexsero (Meningococcal Group B Vaccine [recombinant, adsorbed]) for active...